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Abstract
Backgroud: The detectable rate of minimal gastric GISTs has continuously increased. While the surveillance and
management of GIST <2 cm have been deemed controversial or lack evidence-based approaches. The aim of the
current study is to propose a cut-off value of tumor size for treatment policy and the appropriate timing for
endoscopic ultrasonography (EUS) follow-up in the minimal EUS-suspected gastric GIST patients.
Methods: A single-institution retrospective study was performed. 69 patients with EUS-suspected gastric GISTs were
studied from November 2008 to March 2015. 69 patients with minimal gastric GISTs ≤2 cm diagnosed by EUS were
followed for a mean period of 29 months (range, 12 to 70). An at least 20% increase of the maximal diameter of
the tumors was set as a significant change.
Results: During follow-up, Of the 69 minimal EUS-suspected GISTs, 16 (23.2%) showed significant changes in size.
11 out of 69 GISTs (15.9%), 6 out of 43 GISTs (14.0%), 7 out of 30 GISTs (23.3%) showed significant changes in size,
at 1 year, 2 years, and more than 3 years respectively. The receiver operating characteristic curve analysis showed
that the tumor size cut-off was 9.5 mm. Only 4.7 and 3.7% of gastric EUS-suspected GISTs of <9.5 mm in size
showed significant changes at 1 year and 2 years, while 9.5% at more than 3 years. 34.6, 31.3 and 55.6% of gastric
EUS-suspected GISTs of ≥ 9.5 mm in size showed significant changes at 1 year, 2 years and more than 3 years.
Conclusions: Minimal EUS-suspected GISTs, larger than 9.5 mm may be associated with significant progression.
The patients with a ≥ 9.5 mm GIST should have a EUS 6–12months, while <9.5 mm GIST may have a EUS
extended to every 2–3 years.
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Background
Gastrointestinal stromal tumors (GISTs) are the most com-
mon primary mesenchymal tumors in the gastrointestinal
tract and span a clinical spectrum from benign to malig-
nant. GISTs occur anywhere along the gastrointestinal
tract, but they are most common in the stomach (50–60%)
[1]. Owing to the popularization of EUS, the detectable
rate of gastric GISTs has continuously increased, specific-
ally for minimal gastric GISTs (diameter less than 2 cm).
Surgery is the treatment for primary, local gastric GISTs
larger than 2 cm, while conservative follow-up is suggested
for lesions less than 2 cm. In fact, the National Compre-
hensive Cancer Network (NCCN) and the European
Society of Medical Oncology (ESMO) guidelines for the
surveillance and management of GIST <2 cm have been
deemed controversial or lack evidence-based approaches.
Endoscopic ultrasonography (EUS) has been utilized to
diagnose gastric GISTs with high accuracy, sensibility, and
specificity (87, 95, 72%, respectively) [2, 3]. The typical
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EUS finding of a gastric GIST is a hypoechoic lesion arising
from the fourth layer of the gastric wall. The goal of this
study was to evaluate the malignant potential of minimal
gastric GISTs to determine the best cut-off value for tumor
size and appropriate timing for EUS follow-up, in order to
provide clinical evidence for malignant potential in the
management of minimal gastric GISTs.
Methods
Study design and population
This retrospective study was approved by our institu-
tional ethics committee and meets the guidelines of our
responsible governmental agency. It reviewed data from
patients with minimal gastric GISTs diagnosed by using
EUS at Peking University People’s Hospital between
November 2008 and March 2015.
Tumor size was determined with the maximum diam-
eter obtained by using EUS. The criterion of minimal
gastric GISTs diagnosed by using EUS is a hypoechoic
lesion arising from the fourth layer of the gastric wall.
Every patient had signed a consent form before EUS in-
spection. All EUS image files were reviewed by a single
experienced EUS endoscopist (JW).
Inclusion criteria for this study were: (1) tumor size ≤
2 cm; (2) patients were followed by using EUS at least
twice over a period of 12 months; (3) EUS follow-up period
of more than 1 year. The exclusion criteria were: (1) cancer
patients; (2) diagnosis changed during follow-up. A flow
diagram of the enrolled patients is shown in Fig. 1.
Definitions and study procedure
All enrolled patients were divided into two subgroups
based on the criteria: patients with at least a 20%
increase in the initial maximal diameter of the tumors
during follow-up were included in the progressive dis-
ease group; the other patients were assigned to the
stable disease group. We compared patient demograph-
ics, initial tumor size, tumor location, ultrasonographic
features, and growth rate between the two groups at
1 year, 2 years and more than 3 years respectively. In the
receiver operating characteristic (ROC) curve analysis,
the progressive disease cases were defined as the true
positives, and the stable disease cases were defined as
the true negatives when determining the cut-off value of
the optimal initial size for medical intervention.
Statistical analysis
All statistical analyses were performed with SPSS statis-
tical software (version 20.0 for Windows; SPSS, Chicago,
IL, USA). Numerical variables were expressed as the
mean ± SD unless otherwise stated. Discrete variables
were analyzed using the Chi-square test or Fisher’s exact
test. The optimal cut-off values for tumor size as a prog-
nostic variable were chosen from a ROC curve with the
criterion variable “tumor size” and “progressive disease”
as condition variables. We considered P values <0.05 to
be statistically significant for a two-sided test.
Results
Patient characteristics
A total of 74 patients were diagnosed with minimal gas-
tric GISTs by using EUS meeting the included criteria;
5 patients were excluded for diagnoses changed during
the follow-up. Finally, 69 patients met the criteria for
enrolment (see Table 1). The average age was 59 (range,
27–84) years. There were 17 (21.8%) men and 52
Fig. 1 Flow diagram of enrollment patients
Gao et al. BMC Gastroenterology  (2017) 17:8 Page 2 of 8
(66.7%) women. Tumors were located at the cardia in 7
patients (9.0%), at the fundus in 43 (55.1%) patients, at
the body in 18 (23.1%) patients, and at the pylori in 1
(1.3%) patient. The mean initial tumor size was 8.8
(range, 3–20) mm. Only 4 cases’ (5.8%) initial EUS fea-
tures have the high risk feature, such as heterogeneous
echo texture, irregular extraluminal border, echogenic
foci, and anechoic space. 5 cases (7.2%) were identified
by successfully performing pathological examination of
EUS-FNA. The mean EUS follow-up period was
28 months (range 12–70 months). Of the 69 EUS-
suspected GISTs, 16 (23.2%) showed significant changes
in size (see Table 2). The tumors were mainly located in
the gastric body (9 cases, 56.3%) and fundus (7 cases,
43.7%). Among the cases, 11 patients underwent resec-
tion, and all their tumors proved to be GISTs. While
the other 5 patients refused surgery and were followed
up. Out of 11 patients, 4 patients had lesions with
higher malignant potential, reflected by mitotic rates of
more than 5 per 50 high-power fields (HPFs). Molecu-
lar analysis revealed KIT exon 11 mutation in 10 cases,
and wild type in 1 cases. Moreover, of the 69 EUS-
suspected GISTs, significant change in echo patterns
was observed in 8 patients (11.6%). 6 cases (75%)
showed significant changes in size.
Analysis of the two groups
Out of all, 69, 43 and 30 patients had been followed up
more than 1 year, 2 years and 3 years respectively. When
all the patients were followed up to 1 years, according to
the criteria, there were 58 (84.1%) patients in the stable
disease group and 9 (15.9%) patients in the progressive
disease group (see Table 3). Both groups were similar in
gender, tumor location, and initial EUS features. The
mean age (67.9 vs. 57.6, p = 0.012), initial diameter
(12.6 mm vs. 8.1 mm, p = 0.000), and follow-up EUS
high risk features (45.5% vs. 8.6%, p = 0.001) significantly
predicted progressive disease compared with the stable
Table 1 Clinical characteristics of patients
Characteristics Cases (n = 69)









Initial diameter (mm) 8 (8.8, 3–20)a
Initial EUS features, n (%)
Low-risk features 65 (94.2%)
High-risk features 4 (5.8%)
Follow-up duration (mo) 23 (28, 12–70)a
≥ 12 months, n (%) 69 (100%)
≥ 24 months, n (%) 43 (62.3%)
≥ 36 months, n (%) 30 (43.5%)
aMedian (mean, range)
Table 2 Characteristics of the GISTs that changed in size
No. Sex Age Site Initial Size F/u Size Initial EUS F/u EUS Treatment Final Diagnosis Mitotic count Mutation type
1 M 72 Fundus 6 17 Low risk Low risk OP GIST 7/50HPF KIT exon 11
2 F 75 Body 16 30 Low risk High risk OP GIST 6/50HPF KIT exon 11
3 M 71 Body 20 40 Low risk High risk OP GIST 10/50HPF KIT exon 11
4 F 51 Fundus 8 15 Low risk High risk OP GIST 0/50HPF KIT exon 11
5 F 83 Fundus 7 15 Low risk Low risk Surveillance Not available Not available Not available
6 F 78 Body 11 22 Low risk High risk OP GIST 2/50HPF KIT exon 11
7 M 67 Body 12 17 Low risk Low risk OP GIST 3/50HPF KIT exon 11
8 M 57 Fundus 10 12 Low risk Low risk Surveillance Not available Not available Not available
9 F 51 Fundus 10 13 Low risk Low risk Surveillance Not available Not available Not available
10 F 53 Body 11 15 Low risk Low risk Surveillance Not available Not available Not available
11 M 84 Body 18 35 Low risk High risk OP GIST 3/50HPF KIT exon 11
12 F 57 Body 11 14 Low risk Low risk Surveillance Not available Not available Not available
13 M 67 Body 15 30 Low risk Low risk OP GIST 6/50HPF KIT exon 11
14 M 65 Fundus 10 24 Low risk High risk OP GIST 3/50HPF KIT exon 11
15 F 59 Body 12 15 Low risk Low risk OP GIST 0/50HPF KIT exon 11
16 F 51 Fundus 8 13 High risk High risk OP GIST 2/50HPF Wild-type
Abbreviations: F/u indicates follow-up, HR high risk, IR intermediate risk, LR low risk, OP operation
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disease group. The mean value for the average tumor
growth rate per annum in the progressive disease group
was 50.7%, which was significantly higher than the
−1.2% rate in the stable disease group (p = 0.000). The
data for the two groups are presented in Table 1. When
the patients were followed up to 2 years and more than
3 years (see Tables 4 and 5), we could find similar results
that the age, initial diameter and follow-up EUS high risk
features were significantly predicted progressive disease.
ROC curve analysis
We generated ROC curves to find best the sensitivity
and specificity to detect the optimal cut-off value for
predicting potential tumor growth. For 1 year follow-
up, The area under the curve (AUC) was 0.818, indi-
cating that the best cut-off value of tumor size was
9.5 mm. The sensitivity, specificity, positive predictive
value, negative predictive value, and consistency rates
were 81.8, 70.7, 34.6, 95.3, 72.5%, respectively (see
Fig. 2a). For 2 years and more than 3 years follow-up,
the best cut-off value of tumor size was also 9.5 mm.
The AUC, sensitivity, specificity, positive predictive
value, negative predictive value, and consistency rates
were 0.858, 83.3, 70.3, 31.3, 96.3, 69.8 and 0.786, 82.6,
73.3, 55.6, 90.5, 80.0%, respectively.(see Fig. 2b, c).
Table 3 Characteristics of the minimal EUS-suspected GISTs








Age 57.6 ± 12.3 67.9 ± 11.2 0.012
Gender, n (%) 0.053
Male 9 (17.6%) 8 (44.4%)
Female 42 (82.4%) 10 (55.6%)
Tumor location, n (%)
Cardia 7 (12.1%) 0 0.587
Fundus 39 (67.2%) 4 (36.4%) 0.087
Body 11 (19.0%) 7 (63.6%) 0.005
Antrum 1 (1.7%) 0 1.000
Initial diameter (mm) 8.07 ± 3.11 12.55 ± 4.16 0.000
Initial EUS, n (%) 0.509
Low risk 55 (94.8%) 10 (90.9%)
High risk 3 (5.2%) 1 (9.1%)
F/u EUS, n (%) 0.001
Low risk 53 (91.4%) 6 (54.5%)
High risk 5 (8.6%) 5 (45.5%)
Growth rate per year (%) −1.2 ± 9.7 50.7 ± 33.6 0.000
Table 4 Characteristics of the minimal EUS-suspected GISTs








Age 58.0 ± 11.8 70.7 ± 11.6 0.019
Gender, n (%) 0.164
Male 8 (17.6%) 3 (44.4%)
Female 29 (82.4%) 3 (55.6%)
Tumor location, n (%)
Cardia 6 (16.2%) 0 0.571
Fundus 25 (67.6%) 2 (33.3%) 0.174
Body 6 (16.2%) 4 (66.7%) 0.020
Antrum 0 0 1.000
Initial diameter (mm) 8.14 ± 3.10 13.83 ± 4.83 0.033
Initial EUS, n (%) 1.000
Low risk 35 (94.6%) 6 (100%)
High risk 2 (5.4%) 0
F/u EUS, n (%) 0.007
Low risk 33 (89.2%) 2 (33.3%)
High risk 4 (10.8%) 4 (66.7%)
Growth rate per year (%) −0.8 ± 5.4 37.3 ± 22.1 0.008
Table 5 Characteristics of the minimal EUS-suspected GISTs








Age 59.4 ± 11.8 62.9 ± 10.7 0.487
Gender, n (%) 0.345
Male 5 (21.7%) 3 (42.9%)
Female 18 (78.3%) 4 (57.1%)
Tumor location, n (%)
Cardia 4 (17.4%) 0 0.548
Fundus 16 (69.6%) 4 (57.1%) 0.657
Body 3 (13.0%) 3 (42.9%) 0.120
Antrum 0 0 1.000
Initial diameter (mm) 7.70 ± 2.79 11.86 ± 4.78 0.007
Initial EUS, n (%) 1.000
Low risk 22 (95.7%) 7 (100%)
High risk 1 (4.3%) 0
F/u EUS, n (%) 0.031
Low risk 22 (95.7%) 4 (57.1%)
High risk 1 (4.3%) 3 (42.9%)
Growth rate per year (%) −0.5 ± 3.1 19.1 ± 9.1 0.001
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Fig. 2 Receiver operating characteristic curve. All the receiver operating characteristic curve analyses showed that the tumor size cut-off was
9.5 mm, at 1 year (a), 2 years (b), and more than 3 years (c)
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Surveillance timing
Eleven out of 69 GISTs (15.9%), 6 out of 43 GISTs
(14.0%), 7 out of 30 GISTs (23.3%) showed significant
changes in size, at 1 year, 2 years, and more than 3 years
respectively. With the 9.5 mm cut-off, there was a sig-
nificant difference between the two subgroups. Only
4.7% (2/43) and 3.7% (1/27) of gastric EUS-suspected
GISTs of <9.5 mm in size showed significant changes at
1 year and 2 years, while 9.5% (2/21) at more than 3 years.
34.6% (9/26), 31.3% (5/16) and 55.6% (5/9) of gastric EUS-
suspected GISTs of ≥ 9.5 mm in size showed significant
changes at 1 year, 2 years and more than 3 years.
Discussion
For a long time, the actual incidence of gastrointestinal
stromal tumor (GIST) was underestimated. With the im-
provements in understanding of this disease and exam-
ination methods, the detection rate was increasing. Most
recent studies have suggested the incidence of gastric
GISTs to be between 10 and 20 cases per million, which
is 2–3 times more than the data of 20 years ago [4].This
trend was also showed in minimal GIST especially for
gastric GIST. Based on the data 20 years ago from
Armed Forces Institute of Pathology (AFIP) of US, it has
been reported that of the 1687 tumors with size mea-
surements, 127 (7.5%) were 2 cm or smaller [5]. While
the data 10 years later from the REGISTER study of Italy
showed the rate was up to 18.3%(170/929) [6]. Moreover,
A study from Germany showed among the consecutive
98 autopsy cases, miro-GIST (less than 1 cm) were
found in 22 patients (22.5%) [7]. A latest population-
Based study [8] for milli-GIST (<2 cm) in the National
Cancer Institute’s SEER database showed that the annual
incidence rate of gastric milli-GISTs was 2.6 per 10
million.
Because the natural course of minimal gastric GIST
remains largely unknown, the current management
policy for gastric GISTs <2 cm is usually conservative,
unless tumors grow more than 2 cm or symptoms
occur such as bleeding, acute abdomen, etc. [9]. Des-
pite the patients with minimal gastric GIST are recom-
mend for close surveillance, there are some difficulties
in clinical works. Firstly, some patients would feel anx-
iety, depression and stress for survival with tumor. Sec-
ondly, some patients could not be followed up
regularly for their poor compliance. These cause some
patients to choose the two extremes: excision by over-
treatment or few surveillance with delayed treatment.
Therefore, identification of malignant potential for
minimal gastric GIST is very important. Although most
milli-GISTs are presumed to have less malignant po-
tential especially which with low mitotic rate. If with
high mitotic rate, the metastases rate or tumor-related
mortality would be significantly worse. EUS-guided fine
needle aspiration (EUS-FNA) has been suggested for
the determination of malignant potential in gastric
GISTs with high accuracy (91.7–97%) [10, 11]. While
in these study, the GISTs evaluated were larger ones
>2 cm mostly (80–91%). It would have been difficult to
use EUS-FNA for minimal gastric GISTs. Due to the
small size, success ratio of puncture maybe low. More-
over there would be insufficient tissues obtained by
biopsy to assess mitotic or genetic mutation. Mekky
et al. reported adequate samples were obtained in
67.6% of gastric submucosal tumors with size <20 mm
[12]. Even the adequate specimens were considered,
the reported diagnostic yields for tumors less than
20 mm was 71% [11]. Thus, the diagnosis of miminal
GISTs may be mostly diagnosed based on EUS appear-
ance. Ultrasonographic features are another important
predictive factor of malignancy. High-risk EUS features
include irregular border, cystic spaces, ulceration, echo-
genic foci, and heterogeneity [13]. However, ultrasono-
graphic features might not have been in smaller lesions
as sensitive as for larger ones. In our study, there was
no difference between stable disease group and pro-
gressive disease group regarding initial malignant ultra-
sonographic features. While we found 8 cases showed
ultrasonographic feature changes. They all occurred
after the diameter increased more than 1 cm. Among
them 6 (75.0%) showed significant changes in size.
With knowledge of GIST biological behaviours, we
gradually realized that the malignancy potential of some
minimal gastric GISTs was high, and these need to have
medical intervention. Even some experts suggested sur-
gical resection of all minimal gastric GISTs once diag-
nosed [14]. The growth of the tumor is an important
index of malignant potential. There are some studies
proposing a cut-off value of initial tumor size, in order
to predicting GISTs with significant-sized change. A
retrospective analysis by Lachter et al. [15] reported that
out of 70 GISTs monitored by EUS, enlargement in size
was detected significantly more in GISTs over 17 mm
diameter (P < 0.018) at averaged follow-up examination
23.2 mm. In another retrospective study by Gill et al.
[16], the majority (86.3%) of <3 cm upper gastrointes-
tinal subepithelial tumors (SETs) did not increase in size
and/or change in echogenic features during a median of
23 months. In another study by Kim et al. [17], in 989
gastric subepithelial tumors, SETs of 10 to 30 mm in size
grew significantly more rapidly than SETs <10 mm over
a median period of 24 months when followed up endo-
scopically or by EUS. Fang et al. [18] followed 50 pa-
tients with EUS-suspected gastric GISTs of sizes less
than 3 cm over a period of more than 24 months (range
24–101 months), found that the best cutoff size associ-
ated with tumor progression was 1.4 cm having an
85.7% sensitivity, 86.1% specificity, and 86.0% accuracy.
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While all these studies included the GISTs or SETs
>2 cm. These tumors should be resected without contro-
versy. The current surveillance and management policy
for gastric minimal GISTs is still controversial. So our
study was specific for GISTs ≤2 cm of the stomach.
Moreover most studies above followed the patients over
much different time (range 3 months to more than
5 years). This may increase select bias, because the pos-
sibility of significant increase in tumor size is different
over different time. In this study, all the patients were
followed up over the same time (1 year, 2 years or more
than 3 years). It was also helpful to propose appropriate
timing for endoscopic ultrasonography (EUS) follow-up.
We found Minimal EUS-suspected GISTs larger than
9.5 mm may be associated with significant progression.
Experts recommend EUS surveillance of gastric milli-
GISTs, although there are few data to support surveil-
lance at all. In 2015, NCCN recommended for the pa-
tients with gastric minimal GISTs, EUS surveillance at
6–12 moths intervals may be considered [19]. The study
cited by NCCN analyzed the data of 37 patients with
GISTs, while only 13.5% (5/37) of all GISTs showed
<2 cm in size. Due to insufficient evidences, the latest
edition of the guide by NCCN [9] modified its recom-
mendation description to “consider periodic endoscopic
surveillance”. This new study cited by NCCN was de-
signed as an online survey from all 413 members of the
American Society for Gastrointestinal Endoscopy
(ASGE) EUS Special Interest Group. It showed for le-
sions not resected, 70% survey annually, 19% less than
annually, 10% more than annually, and 1% do not survey
[20]. While this studies also included a lot of GISTs
>2 cm. Based on experts’ preferences, ASGE recom-
mended annual surveillance is commonly practiced [21].
In our study, 15.9, 14.0 and 23.3% GISTs showed sig-
nificant changes in size, at 1 year, 2 years, and more
than 3 years respectively. So we also recommend
endoscopic surveillance annually for all gastric milli-
GISTs. In addition, with the 9.5 mm cut-off, few of
GISTs <9.5 mm (<5%) showed significant size changes
in the first 2 years. On the contrary, numerous
GISTs ≥ 9.5 mm showed significant changes even in
the first year. So ≥ 9.5 mm GIST maybe need a EUS
less than annually. For the patients with <9.5 mm
GIST, EUS surveillance at 2–3 years interval may be
considered. This strategy may increase the quality of
life and enhance the compliance for patients with
smaller milli-GIST.
Some limitations existed in our study. First, few cases
(5/69) enrolled in the study were identified by success-
fully performing pathological examination of EUS-FNA,
due to technical difficulty or insufficient material to
make diagnosis. Although the accuracy of GIST diag-
nosed by using EUS is as high as 87%, [2, 3] this would
influence the results of our study because of some them
might have had benign submucosal tumors, such as leio-
myoma. While in our data, out of 16 tumors with signifi-
cant increase in tumor size located in the fourth layer
on EUS, 11 underwent surgical resection and final
pathological diagnosis was all GISTs. Second, this is a
single-institution retrospective study. Further confirm-
ation of these findings is needed in a larger, multicentre
cohort.
Conclusions
In conclusion, an initial tumor size larger than 9.5 mm was
associated with significant tumor progression and was valu-
able for predicting the malignant potential GIST. According
to our results, the patients with a <9.5 mm GIST may have
a EUS extended to every 2–3 years, while ≥ 9.5 mm GIST
should have a EUS 6–12 months.
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